TOP NEWS: AstraZeneca hires CFO of takeover target Alexion as CFO

(Alliance News) - AstraZeneca PLC on Friday said it has appointed Alexion Pharmaceuticals Inc's ...

Alliance News 4 June, 2021 | 7:32AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC on Friday said it has appointed Alexion Pharmaceuticals Inc's Aradhana Sarin as chief financial officer, as current finance head Marc Dunoyer moves in the other direction.

Sarin is currently the chief financial officer of Alexion, the company AstraZeneca is buying for USD39 billion. She joined the Boston, Massachusetts-based firm in 2017 having previously worked at Citigroup Inc, UBS Group AG and JPMorgan Chase & Co.

She is set to replace Marc Dunoyer as AstraZeneca finance chief. Dunoyer will become chief executive officer of Alexion and chief strategy officer of AstraZeneca, and step down from the board after seven years in the finance role.

Sarin is due to start the job on either August 1 or the date the acquisition closes, whichever comes later.

She will earn GBP850,000 per year, plus up to double the base salary under the company's short-term incentive plan and over four times the base salary under the long-term incentive plan.

"In Aradhana Sarin, we've appointed a talented successor to Marc as an executive director and CFO," AstraZeneca Chair Leif Johansson said.

Shares in AstraZeneca were up 0.1% to 7,959.00 pence in London.

By Ivan Edwards; ivanedwards@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 12,026.00 GBX 5.94
Citigroup Inc 61.79 USD -1.09
UBS Group AG 24.96 CHF -0.24
JPMorgan Chase & Co 193.37 USD 0.15

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures